Based on this knowledge, IDO1 has been considered a therapeutic target, and several inhibitors have been designed aiming to block its catalytic activity, restore immune system function, and improve cancer immunotherapy outcomes [7,8]. The gene discussed is IDO1; the disease is cancer.